Pfizer’s acquisition of Metsera, announced on September 22, 2025, stands out as one of the most significant pharmaceutical deals of the year—propelling the US giant back into the race for transformational obesity drugs after earlier setbacks. The deal offers up to $7.3 billion in total potential value, including milestone-based contingent payments, and reflects a bold…
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
